Novel targets for cardiac antiarrhythmic drug development.

abstract：:With a 2030 projection of 23.6 million deaths per year the prevalence and severity of cardiovascular disease is at an astounding high. Thus, a definitive need for the identification of novel compounds with potential to prevent or treat the disease and associated states. Moreover, there is also an ever-increasing need ...

journal_title：Current pharmaceutical design

authors： Houacine C,Khan I,Yousaf SS

更新日期：2020-09-09 00:00:00

abstract：:Aspirin is an antiplatelet drug, inhibiting the cyclooxygenase activity of platelet prostaglandin H synthase-1 and almost complete suppressing platelet capacity to generate the prothrombotic and proatherogenic thromboxane A2. Antiplatelet therapy with aspirin reduces the risk of serious vascular events by about a quar...

journal_title：Current pharmaceutical design

authors： De Caterina R,Renda G

更新日期：2012-01-01 00:00:00

abstract：:Non-alcoholic fatty liver disease (NAFLD) includes liver diseases ranging from simple steatosis to progressive forms characterized by high rates of complications and mortality, namely fibrosis, cirrhosis and hepatocellular carcinoma. Identification of patients with simple steatosis who will evolve to a more severe liv...

journal_title：Current pharmaceutical design

authors： Lombardi R,Fargion S,Fracanzani AL

更新日期：2020-01-01 00:00:00

abstract：BACKGROUND:Approximately 10-15% of patients on DOACs have to interrupt their anticoagulant before an invasive procedure every year. The perioperative management and monitoring of DOACs have proved to be challenging, as differences in patients' status and in the invasiveness of each procedure develop different situation...

journal_title：Current pharmaceutical design

authors： Kouvelos G,Matsagkas M,Rousas N,Nana P,Mpatzalexis K,Stamoulis K,Giannoukas A,Arnaoutoglou E

更新日期：2018-01-01 00:00:00

abstract：:Natural products remain the best resources of drugs and drug leads. Recently, there is growing recognition that identifying new small molecules to promote bone regeneration is a laudable translational goal. In fact, new approaches for bone repair and regeneration that involve inexpensive naturally-derived compounds wo...

journal_title：Current pharmaceutical design

authors： Awale G,Wong E,Rajpura K,W-H Lo K

更新日期：2017-01-01 00:00:00

abstract：:Cytokines are known to play a key role in regulation of gastric functions. Interferon-alpha (IFN-α) has been published to impair gastric motility. Aims of this study were to clarify effect of IFN-α on gastric acid secretion (GAS) and determine role of nitric oxide (NO) in the process. Both subcutaneous (1000, 10000, 1...

journal_title：Current pharmaceutical design

authors： Czimmer J,Király Á,Szabó IL,Mózsik G,Sütő G

更新日期：2013-01-01 00:00:00

abstract：:Various growth factors such as the platelet derived growth factor (PDGF), insulin-like growth factor (IGF), epidermal growth factor (EGF), fibroblast growth factor (FGF), and vascular endothelial growth factor (VEGF) transduce their mitogenic signals through the activation of tyrosine kinase receptors (RTKs). Since en...

journal_title：Current pharmaceutical design

authors： Gouni-Berthold I,Sachinidis A

更新日期：2004-01-01 00:00:00

abstract：:Inflammation is part of an important mechanism triggered by the innate immune response that rapidly responds to invading microorganisms and tissue injury. One important elicitor of the inflammatory response is the Gram-negative bacteria component lipopolysaccharide (LPS), which induces the activation of innate immune ...

journal_title：Current pharmaceutical design

authors： de Almeida OP Jr,Toledo TR,Rossi D,Rossetto Dde B,Watanabe TF,Galvão FC,Medeiros AI,Zanelli CF,Valentini SR

更新日期：2014-01-01 00:00:00

abstract：:Since their proposal in 1976, sigma (σ) receptors have been increasingly implicated in the pathophysiology of virtually all major central nervous system (CNS) disorders, including anxiety, depression, schizophrenia, and drug addiction. Due to their involvement in motor function and higher cognitive function,σ recepto...

journal_title：Current pharmaceutical design

authors： Banister SD,Kassiou M

更新日期：2012-01-01 00:00:00

abstract：:Parkinson's disease (PD) is a movement disorder caused by degeneration of the nigrostriatal dopamine (DA) neurons in the substantia nigra pars compacta and the resultant deficiency in the neurotransmitter DA at the nerve terminals in the striatum. We and other investigators found increased levels of pro-inflammatory c...

journal_title：Current pharmaceutical design

authors： Nagatsu T,Sawada M

更新日期：2005-01-01 00:00:00

abstract：:In the last two decades a tremendous development has been noticed in our understanding of the purinergic system, consisting of heterogeneously expressed purinoceptor subtypes and its classical agonists: e.g., adenosine triphosphate, uridine triphosphate or complex dinucleoside polyphosphates. These agonists exert mult...

journal_title：Current pharmaceutical design

authors： Schuchardt M,Tölle M,van der Giet M

更新日期：2012-01-01 00:00:00

abstract：:Drug discovery is generally considered as a costly affair and it takes approximately 15 years to reach a new chemical entity into the market. Among the recent potent drug molecules with most effective pharmacological properties, very few reached for Phase I clinical trial in humans. Unfortunately, the historical avera...

journal_title：Current pharmaceutical design

authors： Paudwal G,Rawat N,Gupta R,Baldi A,Singh G,Gupta PN

更新日期：2019-01-01 00:00:00

abstract：:Nanoparticles have gained ground in several fields. However, it is important to consider their potentially hazardous effects on humans, flora, and fauna. Human exposure to nanomaterials can occur unintentionally in daily life or in industrial settings, and the continuous exposure of the biological components (cells, r...

journal_title：Current pharmaceutical design

authors： Mitarotonda R,Giorgi E,Desimone MF,De Marzi MC

更新日期：2019-01-01 00:00:00

abstract：:The octapeptide angiotensin II (Ang II) plays a homeostatic role in the regulation of blood pressure and water and electrolyte balance, and also contributes to the progression of cardiovascular remodeling. Ang II activates Ang II type 1 (AT1) receptor and type 2 (AT2) receptor, both of which belong to the seven-transm...

journal_title：Current pharmaceutical design

authors： Akazawa H,Yano M,Yabumoto C,Kudo-Sakamoto Y,Komuro I

更新日期：2013-01-01 00:00:00

abstract：:Inhaled glucocorticoids, also know as corticosteroids (ICS), revolutionized the treatment of asthma by suppressing airways inflammation and ICS therapy now forms the basis of treatment of asthma of all severities. More recently and usually in combination with a long-acting β-agonist (LABA), ICS use has been establishe...

journal_title：Current pharmaceutical design

authors： Adcock IM,Marwick J,Casolari P,Contoli M,Chung KF,Kirkham P,Papi A,Caramori G

更新日期：2010-01-01 00:00:00

abstract：:Neuregulin1 proteins (NRG1s) are epidermal growth factor (EGF) family members which are ligands for the ErbB receptor tyrosine kinases (RTKs). A decade of research has revealed that the NRG1-ErbB signaling is essential for the cardiac development and pivotal for maintaining the physiological function of the adult hear...

journal_title：Current pharmaceutical design

authors： Yan X,Morgan JP

更新日期：2011-01-01 00:00:00

abstract：:There is now a large body of evidence that weight loss in older persons not only increases mortality, but also increases the incidence of hip fracture, functional deterioration and institutionalization. Weight loss is a central component of frailty. There is evidence that it is not only muscle, but also fat loss that ...

journal_title：Current pharmaceutical design

authors： Morley JE

更新日期：2007-01-01 00:00:00

abstract：:Despite the development of strong antibiotics, the pneumonia death is increasing all over the world in these decades. Among the people who died of pneumonia, the majority were 65 years old or over. Although pneumonia is recently categorized into several entities, aspiration pneumonia includes all entities. Therefore, ...

journal_title：Current pharmaceutical design

authors： Ebihara S,Ebihara T,Gui P,Osaka K,Sumi Y,Kohzuki M

更新日期：2014-01-01 00:00:00

abstract：:Ischaemic stroke of the brain accounts for about one third of all deaths in industrialized countries. Many of the patients who survive are severily impaired. Thus, there is an enormous need for pharmacotherapy for the treatment of ischaemic stroke. Why is such a treatment not available yet? Are the pathophysiological ...

journal_title：Current pharmaceutical design

authors： Weiser T

更新日期：2002-01-01 00:00:00

abstract：:Chronic smoking is associated with functional and structural vascular changes underlying inflammatory processes responsible for plaque formation and rupture. Cyclooxygenase (COX) is the key enzyme linking smoking action to inflammatory damages: it is responsible for the conversion of arachidonic acid to prostanoids, a...

journal_title：Current pharmaceutical design

authors： Pistoia F,Cipollone F,Ferri C,Sarà M,Sudano I,Desideri GB

更新日期：2010-01-01 00:00:00

abstract：:Unhealthy diet and alcohol are serious health problems, especially in adolescents and young adults. "Binge" is defined as the excessive and uncontrolled consumption of food (binge eating) and alcohol (binge drinking). Both behaviors are frequent among young people and have a highly negative impact on health and qualit...

journal_title：Current pharmaceutical design

authors： Escrivá-Martínez T,Herrero R,Molinari G,Rodríguez-Arias M,Verdejo-García A,Baños RM

更新日期：2020-01-01 00:00:00

abstract：:Stroke is a leading cause of death and disability worldwide. Conventional treatment has a limitation of very narrow therapeutic time window and its devastating nature necessitate a novel regenerative approach. Transplanted stem cells resulted in functional recovery through multiple mechanisms including neuroprotection...

journal_title：Current pharmaceutical design

authors： Kwak KA,Kwon HB,Lee JW,Park YS

更新日期：2018-01-01 00:00:00

abstract：:Multidrug resistance (MDR) is a phenomenon through which tumor cells develop resistance against the cytotoxic effects of various structurally and mechanistically unrelated chemotherapeutic agents. The most consistent feature in MDR is overexpression and/or overactivity of ATP-dependent drug efflux transporters. Other ...

journal_title：Current pharmaceutical design

authors： Ghandadi M,Sahebkar A

更新日期：2016-01-01 00:00:00

abstract：:Dioxygen (O2) is an exogenously supplied gas with a number of properties that make it valuable as a biological source of energy and as a result much of life has become dependent on this molecule. Nitric oxide (NO), carbon dioxide (CO) and hydrogen sulfide (H2S) are small molecules that are sometimes in a gaseous state...

journal_title：Current pharmaceutical design

authors： Fukuto JM,Collins MD

更新日期：2007-01-01 00:00:00

abstract：:Telomerase is a specialized enzymatic complex responsible for the synthesis of telomeric repeats 5'-TTAGGG-3' localized at the ends of eukaryotic chromosomes. This mechanism prevents shortening of telomeres after each cell division. The enzyme is detected in about 85% of human tumors, but it is not expressed in normal...

journal_title：Current pharmaceutical design

authors： Romaniuk A,Kopczynski P,Ksiazek K,Rubis B

更新日期：2014-01-01 00:00:00

abstract：:There is initial evidence, at least in cardiac surgery, that total intra-venous anesthesia (usually a propofol-based total intravenous anesthesia) is associated with an increased mortality when compared to an anesthetic plan including a halogenated anesthetics. The cardiac protective properties of halogenated agents (...

journal_title：Current pharmaceutical design

authors： Landoni G,Pasin L,Borghi G,Zangrillo A

更新日期：2014-01-01 00:00:00

abstract：:Integrins alpha(1)beta(1) and alpha(2)beta(1) are highly expressed on the microvascular endothelial cells, and blocking of their adhesive properties significantly reduced the VEGF-driven neovascularization ratio and tumor growth in animal models. Hence, inhibitors of the alpha(1)beta(1) and alpha(2) beta(1) integrins,...

journal_title：Current pharmaceutical design

authors： Calvete JJ,Marcinkiewicz C,Sanz L

更新日期：2007-01-01 00:00:00

abstract：BACKGROUND:Atherosclerosis is a chronic inflammatory disease and a leading cause of coronary artery disease, peripheral vascular disease and stroke. Lipid-laden macrophages are derived from circulating monocytes and form fatty streaks as the first step of atherogenesis. METHODS:An electronic search in major databases ...

journal_title：Current pharmaceutical design

authors： Taghizadeh E,Taheri F,Renani PG,Reiner Ž,Navashenaq JG,Sahebkar A

更新日期：2019-01-01 00:00:00

abstract：:Although the obesity epidemic is constantly expanding at very high costs for health care systems, the currently available options for the pharmacotherapy of obesity are very limited. This is not due to lack of interest or research on the subject but rather to the poor efficacy and/or safety profile of the majority of ...

journal_title：Current pharmaceutical design

authors： Gouni-Berthold I,Brüning JC,Berthold HK

更新日期：2013-01-01 00:00:00

abstract：BACKGROUND:From the evidence of failed injection-based growth factor therapies, it has been proposed that a naturally triggered uninterrupted blood circulation of the growth factors would be superior. OBJECTIVE:We seek to stimulate discussions and more research about the possibility of using the already available grow...

journal_title：Current pharmaceutical design

authors： Muresanu C,Somasundaram SG,Vissarionov SV,Gavryushova LV,Nikolenko VN,Mikhaleva LM,Kirkland CE,Aliev G

更新日期：2020-10-18 00:00:00